{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', '11. Comparison of seroprotection and seroconversion as defined by HAI titers and', 'geometric mean HAI titers between 1 month and 6 months in the same subjects (Year 1', 'only)', '3', 'STUDY DESIGN', '3.1 Main study design', 'This study is a prospective, randomized, blinded clinical trial to assess the safety of allV3', 'versus IIV3-HD in >440 adults age >65 years enrolled at Duke University Medical Center (Lead', 'Contractor), >340 adults age >65 years enrolled at Boston Medical Center (BMC) (Contributing', 'Contractor), and 100 adults age >65 years enrolled at Cincinnati (Contributing Subcontractor).', 'Participants will be enrolled in 2017-18 (Duke and Boston) and 2018-19 (Duke, Boston, and', 'Cincinnati) influenza seasons. Unblinded, licensed staff will perform vaccinations, and all other', 'study personnel and subjects will be blinded throughout the study, with the exception of the', 'Duke Project Manager, Boston Pharmacy, and Cincinnati Pharmacy staff (who have no', 'involvement with study subjects). In addition, the study statistician will be blinded during data', 'analysis. Older adults who have not received IIV during the respective influenza seasons during', 'which they are recruited will be enrolled. Detailed health, demographic and health-related', 'quality of life data will be collected from study participants at baseline prior to influenza vaccine', 'receipt. With Day 1 serving as the day of vaccination, participants will be followed through Day 8', '(total 8 days) for symptoms of reactogenicity as described in Section 5.4. Health-related quality', 'of life and vaccination experience data will be collected during this time period. Participants will', 'be followed through Day 43 for serious adverse events and adverse events of clinical interest,', 'including health care utilization, as described in Sections 5.4 and 5.6.', '3.2 Laboratory Studies', '3.2.1 Influenza Hemagglutination Inhibition Assay', 'Participants will have blood draws on Day 1 (before vaccination) and Day 29 to be', 'stored for serum hemagglutination inhibition (HAI) antibody titers. During 2017-18', 'influenza season (Year 1), a subset of approximately 100 patients at Duke will have', 'a blood draw at Day 181 for an additional HAI titer. If funding is available, HAI', 'antibody titers will be compared between groups receiving allV3 or IIV3-HD for each', 'of the three influenza vaccine strains contained in the respective vaccines for that', 'season. Additionally, if funding available, 60 year 1 participants will receive repeat', 'immunization with the same vaccine in year 2 at Duke, and HAI titers will be', 'performed on serum from Day 1 and Day 29. Participants will not receive individual', 'HAI antibody titer results; these are not routinely used in clinical practice.', '3.2.2', 'Future studies', 'Additional blood will be stored for further immune analyses depending on funding', 'availability. Biologic specimens collected as part of this study and used in other', 'studies examining the immune response to influenza vaccine will be linked to', 'information (including identifying information) that participants provided in the current', 'study. Participants are not expected to receive results of any future testing of their', 'specimens.', '14']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', '4 STUDY ENROLLMENT AND WITHDRAWAL', '4.1 Subject Inclusion Criteria', 'Subjects who meet all of the following criteria will be eligible to participate in this', 'interventional study.', '1. Persons aged >65 years, living in the community', '2. Intention of receiving IIV vaccine based on ACIP-CDC guidelines', '3. Willing to provide written informed consent prior to initiation of any study procedures', '4. Able to speak English', '5. Able and willing to complete baseline assessments and questionnaires, and to allow', 'information to be collected from their electronic medical record', '6. Able and willing to complete post-vaccine assessments and questionnaires', 'independently or with assistance', '7. Able and willing to have blood drawn for the study', '8. Able and willing to return in about one month for a follow-up visit including completing', 'questionnaires and having another blood test', '9. Access to and ability to use a phone, independently or with assistance', '10. Adequate vision and motor skills to complete the symptom diary form independently or', 'with assistance.', '11. Not living in a skilled nursing facility/nursing home/long term acute care facility', '4.2 Subject Exclusion Criteria', 'Subjects who meet any of the following criteria will not be eligible to participate in this', 'study:', '1. Influenza vaccine receipt during the current influenza season prior to study enrollment', '2. Enrolled in this study during the 2017-18 (Year 1) influenza season', 'Note: Year 1 study participant will only be enrolled in Year 2 if they are', 'participating in the sub-study on repeat vaccination', '3. Has immunosuppression as a result of an underlying illness or treatment, or use of anti-', 'cancer chemotherapy or radiation therapy within the preceding 12 months.', '4. Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate', 'cancer that is stable in the absence of therapy) or a history of any hematologic', 'malignancy*', '*Participants with a history of malignancy may be included if, after previous treatment by', 'surgical excision, chemotherapy or radiation therapy, the participant has been observed', \"for a period that in the investigator's estimation provides a reasonable assurance of\", 'sustained cure', '5. Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating', 'intramuscular injection', '6. Receipt of blood or blood-derived products in the past three months', '7. History of febrile illness (> 100.0\u00b0F or 37.8\u00b0C) within the past 24 hours prior to IIV', 'administration (temporary deferral)', '8. Contraindication to IIV receipt including history of severe allergic reaction after a', 'previous dose of any influenza vaccine; or to a vaccine component*, including egg', 'protein; or a latex allergy', '*Formaldehyde, Octylphenol ethoxylate, neomycin, kanamycin, barium,', 'cetyltrimethlyammonium bromide (CTAB)', '9. Any history of Guillain-Barr\u00e9 syndrome', '15']\n\n###\n\n", "completion": "END"}